Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Study describes how hyperactivation of AMPK promotes neurodegeneration in HD

A new study describes how hyperactivation of AMP-activated protein kinase (AMPK) promotes neurodegeneration in Huntington's disease.

19 Jul 2011

Gladstone plans to create new center for Alzheimer's disease research

The Gladstone Institutes today announced plans to create a Center for Comprehensive Alzheimer's Disease Research, offering new hope for the millions of families stricken by this debilitating neurodegenerative disease.

16 Jul 2011

Neuralstem receives U.S. patent allowance for three new neurogenic compounds

Neuralstem, Inc. announced that it has received notice of allowance for U.S. Patent Applications 12/939,897 and 12/939,914 entitled: "Compositions to Effect Neuronal Growth."

15 Jul 2011

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.

11 Jul 2011

Scientists discover way to separate neural wheat from the chaff

University of Florida scientists have discovered a way to separate the neural wheat from the chaff during the process of generating brain cells for potential patient therapies.

8 Jul 2011

Gene overexpression linked with Alzheimer's disease and Down syndrome

Chronic stress has long been linked with neurodegeneration. Scientists at USC now think they may know why.

29 Jun 2011

Scientists uncover new therapeutic target for Huntington's disease

UT Southwestern Medical Center researchers have identified compounds that appear to inhibit a signaling pathway in Huntington's disease, a finding that may eventually lead to a potential drug therapy to help slow the progression of degenerative nerve disorders.

24 Jun 2011

Lithium can prevent aggregation of toxic proteins and cell loss linked with Parkinson's

Lithium profoundly prevents the aggregation of toxic proteins and cell loss associated with Parkinson's disease (PD) in a mouse model of the condition.

24 Jun 2011

AMT receives CHMP opinion on Glybera Marketing Authorisation Application

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera as a potential therapy for Lipoprotein Lipase Deficiency.

24 Jun 2011

Researchers identify natural mechanism linked with Huntington's disease

Johns Hopkins researchers have identified a natural mechanism that might one day be used to block the expression of the mutated gene known to cause Huntington's disease.

22 Jun 2011

Genomic study identifies MCU that regulates calcium transport into mitochondria

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Massachusetts General Hospital (MGH), the Broad Institute, and the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT), today announced new findings published in Nature.

20 Jun 2011

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Neurologix, Inc. announced today several new results from the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) as part of a comprehensive presentation of study findings to the National Institutes of Health (NIH) Recombinant DNA Advisory Committee.

9 Jun 2011

SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189

Neuralstem, Inc. announced that it has signed an exclusive agency licensing agreement with Summit Pharmaceuticals International Corporation, of Tokyo, Japan (SPI), a wholly owned subsidiary of Sumitomo Corporation Group.

8 Jun 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

6 Jun 2011

Medical researchers uncover a novel approach to treat Huntington's disease

Medical researchers may have uncovered a novel approach to treat an incurable and ultimately fatal neurodegenerative disease that affects hundreds of thousands of people.

3 Jun 2011

New slow-release compound protects against Huntington's and Alzheimer's

A study in a special early online publication of Cell, a Cell Press publication, reveals a promising new slow-release compound that protects mice against the neurodegenerative effects of both Huntington's and Alzheimer's disease.

3 Jun 2011

Researchers discover new drug target that may effectively prevent onset of Huntington's disease

McMaster University researchers have discovered a new drug target that may be effective at preventing the onset of Huntington's disease, working much the same way heart medications slow the progression of heart disease and reduce heart attacks.

1 Jun 2011

Insight into new prion formation

Unlocking the mechanisms that cause neurodegenerative prion diseases may require a genetic key, suggest new findings reported by University of Illinois at Chicago distinguished professor of biological sciences Susan Liebman.

27 May 2011

Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress

Neurologix, Inc. announced the presentation today of efficacy results through one year of follow-up in patients treated as part of the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease.

27 May 2011

GIS discovery could help generate stem cells more efficiently for biomedical applications

A team of scientists from Genome Institute of Singapore (GIS) of the Agency for Science, Technology and Research (A*STAR) have shown how proteins involved in controlling genes work together to carry out their functions in stem cells and demonstrated for the very first time, how they can change interaction partners to make other types of cells.

20 May 2011